Free Trial
NASDAQ:RMTI

Rockwell Medical Q3 2026 Earnings Date & Estimates

Rockwell Medical logo
$7.66 -0.19 (-2.42%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$7.71 +0.05 (+0.65%)
As of 06:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rockwell Medical is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET

What Analysts Expect from Rockwell Medical in Q3 2026

Rockwell Medical is expected to post earnings of -$0.13 per share on revenue of $18.22 million. Rockwell Medical last reported on August 13, 2026, posting -$0.34 per share and missing the -$0.2350 consensus estimate. Rockwell Medical has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.13
Expected Revenue
$18.22 million

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.34 (Missed by -$0.1050)
Last Quarter Revenue
$17.78 million
EPS Beat Rate
2 of last 8 quarters

Rockwell Medical Q3 2026 Earnings FAQ

Rockwell Medical (NASDAQ:RMTI) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Rockwell Medical's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Rockwell Medical to post earnings of -$0.13 per share for Q3 2026.

The consensus revenue estimate for Rockwell Medical is $18.22 million for Q3 2026.

Rockwell Medical Earnings Headlines

Rockwell Medical to Exhibit at ASN Kidney Week 2026
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More Rockwell Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rockwell Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rockwell Medical and other key companies, straight to your email.

About Rockwell Medical

Rockwell Medical (NASDAQ:RMTI) is a biopharmaceutical company focused on developing and commercializing products for the treatment of iron deficiency and anemia associated with chronic kidney disease, particularly in patients receiving hemodialysis. The company’s products are designed to support iron management while addressing the needs of dialysis providers and their patients.

Rockwell Medical’s principal products include Triferic, an iron replacement therapy delivered through the dialysate during hemodialysis, and Triferic AVNU, an intravenous formulation. The company also supplies dialysis-related products, including concentrates used in the preparation of dialysate. Its commercial activities have primarily centered on the U.S. dialysis market.

Founded in 1996, Rockwell Medical is headquartered in Wixom, Michigan. The company has historically focused its research, regulatory, and commercial efforts on therapies and products intended to improve the management of anemia and iron balance in people with kidney disease.

View Rockwell Medical Profile